Literature DB >> 29244019

Prevalence, healthcare resource utilization and overall burden of fungal meningitis in the United States.

Lefko T Charalambous1, Alykhan Premji1, Caroline Tybout1, Anastasia Hunt1, Drew Cutshaw1, Aladine A Elsamadicy1, Siyun Yang2, Jichun Xie2, Charles Giamberardino3, Promila Pagadala1, John R Perfect3, Shivanand P Lad1.   

Abstract

PURPOSE: Previous epidemiological and cost studies of fungal meningitis have largely focused on single pathogens, leading to a poor understanding of the disease in general. We studied the largest and most diverse group of fungal meningitis patients to date, over the longest follow-up period, to examine the broad impact on resource utilization within the United States.
METHODOLOGY: The Truven Health Analytics MarketScan database was used to identify patients with a fungal meningitis diagnosis in the United States between 2000 and 2012. Patients with a primary diagnosis of cryptococcal, Coccidioides, Histoplasma, or Candida meningitis were included in the analysis. Data concerning healthcare resource utilization, prevalence and length of stay were collected for up to 5 years following the original diagnosis.
RESULTS: Cryptococcal meningitis was the most prevalent type of fungal meningitis (70.1 % of cases over the duration of the study), followed by coccidioidomycosis (16.4 %), histoplasmosis (6.0 %) and candidiasis (7.6 %). Cryptococcal meningitis and candidiasis patients accrued the largest average charges ($103 236 and $103 803, respectively) and spent the most time in the hospital on average (70.6 and 79 days). Coccidioidomycosis and histoplasmosis patients also accrued substantial charges and time in the hospital ($82 439, 48.1 days; $78 609, 49.8 days, respectively).
CONCLUSION: Our study characterizes the largest longitudinal cohort of fungal meningitis in the United States. Importantly, the health economic impact and long-term morbidity from these infections are quantified and reviewed. The healthcare resource utilization of fungal meningitis patients in the United States is substantial.

Entities:  

Keywords:  candida meningitis; coccidioides meningitis; cryptococcal meningitis; fungal meningitis; healthcare resource utilization; histoplasma meningitis; infectious disease; prevalence

Mesh:

Year:  2017        PMID: 29244019      PMCID: PMC6557145          DOI: 10.1099/jmm.0.000656

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  13 in total

Review 1.  How Environmental Fungi Cause a Range of Clinical Outcomes in Susceptible Hosts.

Authors:  Steven T Denham; Morgan A Wambaugh; Jessica C S Brown
Journal:  J Mol Biol       Date:  2019-05-09       Impact factor: 5.469

2.  Efficacy of Cerebrospinal Fluid Beta-d-Glucan Diagnostic Testing for Fungal Meningitis: a Systematic Review.

Authors:  Christian Davis; L Joseph Wheat; Thein Myint; David R Boulware; Nathan C Bahr
Journal:  J Clin Microbiol       Date:  2020-03-25       Impact factor: 5.948

3.  Novel Treatment of Cryptococcal Meningitis via Neurapheresis Therapy.

Authors:  Gordon J Smilnak; Lefko T Charalambous; Drew Cutshaw; Alykhan M Premji; Charles D Giamberardino; Christi G Ballard; Andrew P Bartuska; Tiffany U Ejikeme; Huaxin Sheng; Laura Zitella Verbick; Blake A Hedstrom; Promila C Pagadala; Aaron R McCabe; John R Perfect; Shivanand P Lad
Journal:  J Infect Dis       Date:  2018-08-24       Impact factor: 5.226

Review 4.  Fungal infections in pediatric neurosurgery.

Authors:  Adrian Caceres; Maria Luisa Avila; Marco Luis Herrera
Journal:  Childs Nerv Syst       Date:  2018-08-18       Impact factor: 1.475

5.  Evaluation of Rat Brain Morphology Following the Induction of Acute Meningitis Treated with Ceftriaxone.

Authors:  A A Agarkova; A V Tverskoi; V N Morozov; A V Tverskaya; E N Morozova; T S Mukhina
Journal:  Arch Razi Inst       Date:  2021-10-31

Review 6.  The leptomeninges as a critical organ for normal CNS development and function: First patient and public involved systematic review of arachnoiditis (chronic meningitis).

Authors:  Carol S Palackdkharry; Stephanie Wottrich; Erin Dienes; Mohamad Bydon; Michael P Steinmetz; Vincent C Traynelis
Journal:  PLoS One       Date:  2022-09-30       Impact factor: 3.752

7.  Synthesis of analogs of the Gwt1 inhibitor manogepix (APX001A) and in vitro evaluation against Cryptococcus spp.

Authors:  Michael Trzoss; Jonathan A Covel; Mili Kapoor; Molly K Moloney; Quinlyn A Soltow; Peter J Webb; Karen Joy Shaw
Journal:  Bioorg Med Chem Lett       Date:  2019-10-14       Impact factor: 2.823

8.  Estimation of Direct Healthcare Costs of Fungal Diseases in the United States.

Authors:  Kaitlin Benedict; Brendan R Jackson; Tom Chiller; Karlyn D Beer
Journal:  Clin Infect Dis       Date:  2019-05-17       Impact factor: 9.079

Review 9.  Methods for rapid diagnosis of meningitis etiology in adults.

Authors:  Victoria Poplin; David R Boulware; Nathan C Bahr
Journal:  Biomark Med       Date:  2020-04-09       Impact factor: 2.851

10.  In Vitro and In Vivo Evaluation of APX001A/APX001 and Other Gwt1 Inhibitors against Cryptococcus.

Authors:  Karen Joy Shaw; Wiley A Schell; Jonathan Covel; Gisele Duboc; C Giamberardino; Mili Kapoor; Molly Moloney; Quinlyn A Soltow; Jennifer L Tenor; Dena L Toffaletti; Michael Trzoss; Peter Webb; John R Perfect
Journal:  Antimicrob Agents Chemother       Date:  2018-07-27       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.